SciLifeLab, KTH Royal Institute of Technology: Tuuli Lappalainen
Tuuli Lappalainen has been appointed as director of the National Genomics Infrastructure (NGI) at the Science for Life Laboratory (SciLifeLab) in Sweden. She will also become a professor of chemistry, biotechnology, and health at the KTH Royal Institute of Technology School of Engineering Sciences. Lappalainen, who is currently a core member of the New York Genome Center and an associate professor of systems biology at Columbia University, will take up her new posts May 15. She will continue to be an associate faculty member of the NYGC and will maintain her lab at the center.
Stilla Technologies: Philippe Mourere, Rémi Dangla
Stilla Technologies has appointed Philippe Mourere as CEO, to replace founder and CEO Rémi Dangla. Mourere has 25 years of diagnostics executive experience at firms such as HalioDx, Ultivue, Cell Signaling Technology, PerkinElmer, and Caliper Life Sciences. Dangla has been appointed Stilla's chief technology officer and remains a member of the board of directors.
GenapSys: Jason Myers, Hesaam Esfandyarpour
GenapSys has named Jason Myers CEO, effective Feb. 15, 2021, replacing founder Hesaam Esfandyarpour. Myers will also join the board of directors.
Myers comes to GenapSys from Invitae, where he was president of oncology. Prior to that, he was president and CEO of ArcherDx, which he also cofounded, until Invitae acquired the company last October. He also previously held positions at Ion Torrent, and holds a doctorate molecular pharmacology from Stanford University. Myers will continue to serve on Invitae's board of directors.
Esfandyarpour, who served as CEO since 2010, will remain as GenapSys' chairman.
Rheonix: Roy Proujansky, Irving Nachamkin
Rheonix has named Roy Proujansky and Irving Nachamkin to its board of directors. Proujansky has served for more than 30 years in physician, hospital, and health system leadership positions. At Nemours Children's Hospital, his roles included chief executive for the physician practice, chief operating officer for the Nemours Children's Health System, and chief executive for the DuPont Hospital for Children and Delaware Valley Operations. He is currently a professor of pediatrics at the Sidney Kimmel College of Medicine at Thomas Jefferson University.
Nachamkin is professor emeritus of pathology and laboratory medicine and the immediate past director of the division of laboratory medicine and associate director of the clinical microbiology laboratory at the Perelman School of Medicine and Hospital of the University of Pennsylvania. He is an expert in clinical microbiology with a focus on laboratory diagnostics, molecular diagnostics in infectious diseases, and laboratory management, and is a fellow of the American Academy of Microbiology, Infectious Diseases Society of America, and College of Physicians of Philadelphia.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.